Introduction {#S1}
============

Acute mountain sickness (AMS) is a prevalent disease among travelers exposed to high altitudes of \>2,500 m and presents as a combination of several symptoms, such as headache, dizziness, gastrointestinal symptoms, and fatigue ([@B40]). The incidence of this disease varies from 16 to 100%, and depends on several factors, such as the speed of ascent, altitude, and individual predisposition ([@B12]; [@B32]; [@B35]; [@B49]; [@B40]). The severe forms of AMS can lead to high altitude cerebral edema in the travelers, having life-threatening consequences ([@B3]; [@B27]; [@B36]). Indeed, AMS has become a crucial public health problem owing to a significant rise in the number of travelers ascending per year ([@B32]; [@B16], [@B15]). As such, discriminating individuals who are not developing (AMS resistance, AMS−) from developing AMS (AMS susceptibility, AMS+) pre-exposed to high altitudes would be vital for disease prevention. Presently, the knowledge on AMS resistance and susceptibility is limited to some physiological parameters and gene polymorphisms ([@B57]; [@B23]; [@B9]; [@B22]; [@B25]; [@B30]; [@B33]; [@B2]; [@B45]; [@B56]). However, due to the low sensitivity and specificity, their clinical applications are limited ([@B10]; [@B42]). Thus, there is an unmet need to find a convenient and efficient biomarker for identifying AMS− individuals at baseline.

MicroRNA (miRNA) are 21∼23-nucleotide long, single-stranded, non-coding RNA, which are an important class of gene-modulators for various physiological and disease processes, such as cell cycle, growth, development, differentiation, apoptosis, and inflammatory response ([@B58]; [@B50]). In the recent years, miRNA has been found to be stably expressed in saliva, thus being proven as a convenient and non-invasive biomarker for cancer, Sjögren's syndrome, concussion symptoms, and aging ([@B51]; [@B53], [@B54]; [@B31]; [@B1]; [@B17]; [@B20]). Importantly, our recent study on plasma miRNA array has demonstrated that 16 miRNAs were up-regulated and 15 were down-regulated in AMS− individuals at baseline ([@B28]). Specifically, our pilot study involved the evaluation of the salivary expression levels of the five topmost up-regulated miRNAs, which led to the identification of miR-134-3p and miR-15b-5p as abundantly expressed in both whole saliva and its supernatant.

Based on these findings, we hypothesized that salivary miR-134-3p and miR-15b-5p may aid in discriminating between AMS− and AMS+. Therefore, the aims of the present study were to examine whether salivary miR-134-3p and miR-15b-5p could be identified as non-invasive biomarkers for predicting AMS− individuals at baseline, and to evaluate their discriminatory powers. Moreover, as hypoxia is the triggering factor for AMS, the present study also explored the association between cerebral tissue oxygenation indices (TOI) and AMS development after exposed to high altitude.

Materials and Methods {#S2}
=====================

Participants {#S2.SS1}
------------

Participants were recruited according to the inclusion and exclusion criteria. The inclusion criteria involved healthy individuals, without primary residence at an elevation of ≥1,000 m. Exclusion criteria were listed as follows: individuals with history of travel to an elevation of \>2,500 m in the last 2 years, cardio-cerebrovascular diseases, respiratory diseases, kidney diseases, liver diseases, and neuropsychological diseases. In total, 124 healthy Chinese men aged 20--23 years were recruited in the present study.

This study protocol was approved by the Third Military Medical University Ethics Committee, China, meeting with the requirements of the Declaration of Helsinki, and all individuals signed informed consent forms before entry.

Study Procedures {#S2.SS2}
----------------

Following the methods of previous studies ([@B7]; [@B6]), all participants were exposed at the simulated high altitude of 4,500 m \[hypobaric chamber (Feng Lei, Guizhou, China), temperature: 23--25°C, humidity: 23--27%\] for 12 h \[the time of ascending from baseline (200 m) to 4,500 m is 40 min\]. At baseline (8:00 a.m.), blood sample, saliva sample, demographic data, and physiological parameters were collected from the participants. After a 12 h-exposure at 4,500 m (8:40 p.m.), the participants were subjected to diagnosis of AMS, measurement of physiological parameters, and collection of blood sample ([Figure 1](#F1){ref-type="fig"}). During the investigation, participants were provided with the same diet (no coffee, tea, or alcohol drinks), and required to avoid strenuous physical activity. Security assurances, accompanying physicians, immediate evacuation, and medical treatment were available.

![Trial flow diagram. AMS+, participant with acute mountain sickness (AMS); AMS--, participant without AMS; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; LLS, Lake Louise Score; BP, blood pressure; HR, heart rate; SpO~2~, pulse oxygen saturation; TOI, tissue oxygenation indices.](fphys-10-00898-g001){#F1}

Clinical Data Collection and AMS Diagnosis {#S2.SS3}
------------------------------------------

At baseline, a self-reported questionnaire was used to record the demographic data (i.e., age, body mass index \[BMI\], smoking, and drinking history). After the 12 h-exposure at 4,500 m, our accompanying physicians evaluated the AMS of individuals. It was assessed based on Lake Louise Scoring System, which comprises a questionnaire and a scorecard that determine severity ([@B40]). As per the diagnostic criteria, the score was calculated as a combination of headache, dizziness, fatigue, and gastrointestinal symptoms ([@B40]). Finally, the participants with headache and a score ≥3 points, were diagnosed with AMS (AMS+). Participants who had no headache or a score \<3 were classified as AMS−, i.e., without AMS.

Physiological Measurements {#S2.SS4}
--------------------------

The basic physiological parameters, including heart rate (HR), pulse oxygen saturation (SpO~2~), diastolic blood pressure (DBP), and systolic blood pressure (SBP), were measured by our accompanying doctors with a sphygmomanometer (HEM-6200, OMRON, China) and a pulse oximeter (NONIN-9550, Nonin Onyx, United States). Cerebral TOI for the left and right brain were measured using continuous wave near-infrared spectroscopy (NIRO-200NX, Hamamatsu Photonics, Japan). In detail, two sensors were attached to each participant, one on the left and the other on the right forehead (approximately 2.5 cm above the eyebrows) and held gently with a double-sided tape. The sampling frequency and time duration were 50 Hz and 5 min, respectively. TOI was computed using a spatially resolved spectroscopy algorithm and defined as oxygenated hemoglobin as a percentage of total hemoglobin, which represents the mixed oxygenation level of the cerebral compartments. Finally, the mean value of TOI within 5 min was used in the present study. The participants rested for 30 min before the evaluation. In total, our tests have been conducted at baseline (8:00 a.m.) and at 4,500 m (8:40 p.m.), separately. Moreover, all the instruments were validated by a medical device engineer.

Samples Collection and White Blood Cell Count Measurements {#S2.SS5}
----------------------------------------------------------

At baseline, up to 5 mL of saliva sample was obtained in a 50-mL centrifuge tube from each individual. In order to stimulate glandular salivary flow, the cotton swab with 2% citric acid solution was provided, which is used to touch the bilateral posterior lateral surfaces of the tongue (5 s every 30 s) ([@B53]). Then, a total of 2 mL of saliva was removed from the tube as whole saliva sample. The remaining 3 mL of saliva sample was centrifuged at a speed of 3,000 × *g* for 15 min under 4°C, to spin down the exfoliated cells. After that, the supernatant was further centrifuged (12,000 × *g*, 10 min, 4°C) to completely remove the cellular components. Finally, the samples (whole saliva and supernatant saliva) were aliquoted into RNase/DNase free Eppendorf tubes and stored at −80°C until assay. Based on the previous methods of [@B53], [@B55], using citric acid in cotton swab can stimulate glandular salivary flow, but does not alter the results. At baseline and after the exposure at 4,500 m, venous blood samples were collected from the participants by qualified nurses using EDTA-coated tubes and standard procedures. The blood samples were stored at 4°C until further testing. Then, the white blood cell count (WBC) was analyzed using the AU-2700 analyzers (Olympus, Tokyo, Japan) and commercial reagents.

RNA Extraction and qRT-PCR Assay {#S2.SS6}
--------------------------------

Before RNA was isolated from the whole saliva or supernatant saliva samples, 3.5 μl of the working solution of synthetic *Caenorhabditis elegans* miRNA, cel-miR-39 (Qiagen, Valencia, CA, United States), was added as a control. Then, similar to a previous study ([@B13]), miRNeasy extraction kit (Qiagen, Valencia, CA, United States) was used to isolate the total RNA from samples based on the instruction of the manufacturer. For qRT-PCR assay, the Bulge-Loop^*TM*^ miRNA qRT-PCR Starter Kit (including primers) (Ribobio, Guangzhou, China) was used for reverse transcription and iQ^*TM*^5 Real-Time PCR Detection System (Bio-Rid, United States) was used for performing quantitative real-time PCR. Data was analyzed according to the 2^--Δ*CT*^ method.

MIRNA Target Computational Analysis {#S2.SS7}
-----------------------------------

In order to explore the biological functions of miR-134-3p and miR-15b-5p, we predicted the target genes of these miRNAs by employing microT-CDS v5.0, which is the new version of the microserver and has been significantly enhanced with an improved target prediction algorithm ([@B47]; [@B39]; [@B1]). Then, these target genes were enriched into gene ontology (GO) biological processes using the software DIANA-miRPath v3.0 ([@B48]).

Statistical Analysis {#S2.SS8}
--------------------

Shapiro--Wilk's test was used for calculating the normality of all data. Then, the normally distributed data was expressed as mean ± standard deviation, while the non-normally distribution was expressed as median (interquartile range). For the normally distributed data, the independent *t*-test was used to compare the differences whereas for the non-normally distributed data, the Mann--Whitney *U* test was employed. Spearman's correlation and Pearson's correlation were carried out for analyzing relationships between the AMS severity and variables. Univariate logistic regression was used to identify the protectors for AMS. Then, a multivariant logistic regression with enter method was used to confirm independent protectors. Receiver operating characteristic (ROC) curve was applied for each miRNA and the combination. Areas under the ROC curve (AUC) and 95% confidence interval (CI) were calculated to evaluate the power of miRNAs for distinguishing AMS− from AMS+ groups. Statistical analyses were performed with IBM SPSS Statistics 19 (SPSS, Chicago, IL, United States), and MedCalc Statistical Software version 15.4 (MedCalc Software bvba, Ostend, Belgium). *p* \< 0.05 was considered statistically significant.

Results {#S3}
=======

Demographic Data and Clinical Characteristics of Participants {#S3.SS1}
-------------------------------------------------------------

In the present study, the incidence of AMS is 60.5% (75 out of 124). There was no significant difference between AMS+ and AMS− groups in age (21.44 ± 0.66 vs. 21.55 ± 0.78, *p* = 0.664), BMI (22.43 ± 2.72 vs. 22.27 ± 1.86, *p* = 0.500), smoking (66.7 vs. 65.3%, *p =* 0.888), and drinking rate (76.0 vs. 77.5%, *p* = 0.843). Moreover, in comparison with the AMS− group, the AMS+ group had higher LLS (5.57 ± 2.08 vs. 1.69 ± 0.98, *p* \< 0.001, [Table 1](#T1){ref-type="table"}). For all baseline parameters, there was no significant difference between the two groups. Regarding the physiological parameters at 4,500 m, SpO~2~ and the cerebral TOIs, were significantly higher in AMS− group, as compared to the AMS+ group (all *p* \< 0.05, [Table 2](#T2){ref-type="table"}).

###### 

Characteristics of participants.

                         **AMS+ (75)**   **AMS− (49)**   ***p* value**
  ---------------------- --------------- --------------- ---------------
  **Demographic data**                                   
  Age (year)                                             
  Mean                   21.44 ± 0.66    21.55 ± 0.78    0.664
  Range                  20--23          20--23          
  BMI (kg/m^2^)          22.43 ± 2.72    22.27 ± 1.86    0.500
  Smoker (yes)           50 (66.7%)      32 (65.3%)      0.888
  Drinker (yes)          57 (76.0%)      38 (77.5%)      0.843
  **AMS severity**                                       
  LLS                    5.57 ± 2.08     1.69 ± 0.98     \<0.001^∗∗∗^

AMS+, participant with acute mountain sickness (AMS); AMS−, participant without AMS; BMI, body mass index; LLS, Lake Louise Score.

∗∗∗

Means LLS are significantly different between AMS+ and AMS− groups at 4,500 m with

p

value \< 0.001. Data was expressed as means ± standard deviations.

###### 

Difference of physiological parameters between AMS+ and AMS− groups.

                          **AMS+**        **AMS−**                          
  ----------------------- --------------- ---------------- ---------------- ------------------
  SBP (mmHg)              118.67 ± 9.50   115.01 ± 13.78   118.32 ± 10.15   116.73 ± 10.90
  DBP (mmHg)              70.78 ± 7.45    68.17 ± 11.05    70.79 ± 7.46     72.00 ± 8.15
  HR (beat/min)           66.98 ± 9.50    89.03 ± 11.49    66.14 ± 8.59     86.67 ± 12.98
  SpO~2~ (%)              98.04 ± 1.13    80.05 ± 6.66     98.32 ± 0.90     82.71 ± 5.69^\*^
  Left brain TOI (%)      72.35 ± 4.36    60.90 ± 5.13     71.47 ± 4.58     63.43 ± 4.89^∗∗^
  Right brain TOI (%)     72.21 ± 4.98    60.39 ± 4.50     70.67 ± 5.27     62.02 ± 4.06^∗∗^
  Average brain TOI (%)   72.00 ± 5.50    60.65 ± 4.52     71.07 ± 4.04     62.72 ± 3.84^∗∗^

AMS+, participant with acute mountain sickness (AMS); AMS−, participant without AMS; BP, blood pressure; SBP, systolic BP; DBP, diastolic BP; HR, heart rate; SpO

2

, pulse oxygen saturation; TOI, tissue oxygenation indices.

\*

Means parameters are significantly different between AMS+ and AMS− groups at 4,500 m with

p

value \< 0.05;

∗∗

Means parameters are significantly different between AMS+ and AMS− groups at 4,500 m with

p

value \< 0.01.

Differences in Salivary miR-134-3p and miR-15b-5p Between AMS+ and AMS− Groups {#S3.SS2}
------------------------------------------------------------------------------

Upon employing cel-miR-39 as the normalization control, the results of qRT-PCR assay revealed that miR-134-3p (*p* \< 0.001) and miR-15b-5p (*p* \< 0.05) of whole saliva (W-miR-134-3p and W-miR-15b-5p) were significantly up-regulated in the AMS− group as compared to the AMS+ group. Similarly, miR-134-3p and miR-15b-5p of supernatant saliva (S-miR-134-3p and S-miR-15b-5p) were also significantly up-regulated (all *p* \< 0.001, [Figure 2](#F2){ref-type="fig"}).

![Salivary miR-134-3p and miR-15b-5p were different between acute mountain sickness (AMS+) and non-acute mountain sickness (AMS--) groups. These miRNAs were significantly down-regulated in AMS+ group (*n* = 75) compared with AMS-- group (*n* = 49). A non-parametric test (Mann--Whitney *U* test) was employed to compare miRNAs in these two independent groups. Data was expressed as median (interquartile range). The expression level of W-miR-134-3p, S-miR-134-3p and S-miR-15b-5p were significantly different between AMS+ and AMS-- groups at baseline with *p* value \< 0.01. The expression level of W-miR-15b-5p were significantly different between AMS+ and AMS-- groups at baseline with *p* value \< 0.05. S-miR-134-3p: miR-134-3p of supernatant saliva; S-miR-15b-5p: miR-15b-5p of supernatant saliva; W-miR-134-3p: miR-134-3p of whole saliva; W-miR-15b-5p: miR-15b-5p of whole saliva.](fphys-10-00898-g002){#F2}

Salivary MiRNA Signature for Discriminating AMS− From AMS+ Individuals {#S3.SS3}
----------------------------------------------------------------------

Receiver operating characteristic curves were computed to evaluate the power of miRNAs for discriminating AMS− from AMS+ individuals. The AUC of W-miR-134-3p, W-miR-15b-5p, S-miR-134-3p, and S-miR-15b-5p was 0.747, 0.601, 0.767, and 0.703, respectively ([Figures 3A--D](#F3){ref-type="fig"}).

![ROC curve analysis for salivary miRNAs to discriminate AMS-- from AMS+ groups. **(A)** ROC curve analysis for W-miR-134-3p. **(B)** ROC curve analysis for W-miR-15b-5p. **(C)** ROC curve analysis for S-miR-134-3p. **(D)** ROC curve analysis for S-miR-15b-5p. AUC, area under curve; CI, confidence interval.](fphys-10-00898-g003){#F3}

To improve the accuracy of identification, we performed ROC curves for the combination of S-miR-134-3p and S-miR-15b-5p, using logistic regression analysis. Notably, the combination resulted in a robustly increased AUC (0.811), leading to a unique signature for identifying AMS− individuals ([Figure 4](#F4){ref-type="fig"}).

![ROC curve analysis for the combination of S-miR-134-3p and S-miR-15b-5p to discriminate AMS-- from AMS+ groups. AUC, area under curve; CI, confidence interval.](fphys-10-00898-g004){#F4}

Salivary miR-134-3p and miR-15b-5p as Protectors for AMS Development {#S3.SS4}
--------------------------------------------------------------------

The univariate logistic regression analyses revealed that higher expression levels of W-miR-15b-5p, S-miR-15b-5p, and the combination (S-miR-134-3p + S-miR-15b-5p) were protectors for AMS development (all *p* \< 0.05). Furthermore, multivariate logistic regression analyses showed that higher expression levels of S-miR-15b-5p at baseline were independent protectors for AMS (all *p* \< 0.05, [Table 3](#T3){ref-type="table"}). Moreover, higher expression levels of W-miR-134-3p, S-miR-134-3p might be possible protectors for AMS, which need to be studied in the future.

###### 

Univariate and multivariate logistic regression for salivarymiRNAs at baseline (*n* = 124).

                                                  **95% CI**                   
  -------------------------------------- -------- ------------ ------- ------- --------------
  **Univariate logistic regression**                                           
  W-miR-134-3p                           −0.009   0.991        0.985   0.996   0.001^∗∗^
  W-miR-15b-5p                           −0.123   0.884        0.790   0.989   0.032^\*^
  S-miR-134-3p                           −0.007   0.993        0.990   0.996   \<0.001^∗∗∗^
  S-miR-15b-3p                           −1.090   0.336        0.162   0.699   0.004^∗∗^
  Combination                            −5.447   0.004        0.001   0.032   \<0.001^∗∗∗^
  **Multivariate logistic regression**                                         
  W-miR-134-3p                           −0.006   0.994        0.988   0.999   0.044^\*^
  S-miR-134-3p                           −0.006   0.994        0.991   0.998   0.001^∗∗^
  S-miR-15b-3p                           −1.029   0.357        0.149   0.856   0.021^\*^

CI, confidence interval; S-miR-134-3p, miR-134-3p of supernatant saliva; S-miR-15b-5p, miR-15b-5p of supernatant saliva; W-miR-134-3p, miR-134-3p of whole saliva; W-miR-15b-5p, miR-15b-5p of whole saliva. Combination: S-miR-134-3p+ S-miR-15b-5p. For univariate and multivariate logistic regression, the dependent variable is AMS development (1 = AMS+, 0 = AMS−).

\*

p

value \< 0.05;

∗∗

p

value \< 0.01;

∗∗∗

p

value \< 0.001.

Biological Process Regulated by miR-134-3p and miR-15b-5p {#S3.SS5}
---------------------------------------------------------

The GO enrichment analysis exhibited that miR-134-3p and miR-15b-5p could regulate biological processes associated with the inflammatory response, such as the innate immune response (GO:0045087), toll-like receptor 10 signaling pathway (GO:0034166), toll-like receptor TLR1:TLR2 signaling pathway (GO:0038123), toll-like receptor TLR6:TLR2 signaling pathway (GO:0038124), toll-like receptor 5 signaling pathway (GO:0034146), toll-like receptor 9 signaling pathway (GO:0034162), toll-like receptor 2 signaling pathway (GO:0034134), toll-like receptor 4 signaling pathway (GO:0034142), TRIF-dependent toll-like receptor signaling pathway (GO:0035666), MyD88-independent toll-like receptor signaling pathway (GO:0002756), toll-like receptor 3 signaling pathway (GO:0034138), and stress-activated MAPK cascade (GO:0051403) ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

Discussion {#S4}
==========

This is the first study, so far, to report that (i) salivary miR-134-3p and miR-15b-5p were significantly up-regulated in AMS− individuals at baseline; (ii) both salivary miR-134-3p and miR-15b-5p served as non-invasive biomarkers for discriminating AMS− from AMS+ individuals pre-exposed to high altitudes; and (iii) AMS− individuals were featured with higher value of cerebral TOIs.

Nowadays, the biological relevance of miRNAs in body fluid circulation is regarded as a global, hormone-like functional molecule, which might regulate gene expression across tissues ([@B46]; [@B55]). Here, we found that the expression values of salivary miR-134-3p and miR-15b-5p in the AMS− individuals, were significantly higher in the AMS− than the AMS+ individuals. Their target genes were enriched in toll-like receptor signaling pathway and stress-activated MAPK pathway, which are major signaling pathways for modulating inflammation ([@B37]; [@B24]).

Previous studies affirm that increased vascular permeability due to hypoxia-induced inflammation is involved in the pathophysiology of AMS development ([@B21]; [@B5]; [@B29]). Recently, our study found that the concentration of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, are positively correlated to AMS severity ([@B43]). Moreover, another important point to note from our recent study regarding transcriptome analysis is that immune and inflammatory responses are overrepresented in AMS+ individuals, but not in AMS− ([@B27]). Intriguingly, dexamethasone, the first line treatment for AMS, has proven to be quite effective in producing an anti-inflammatory response via inhibiting toll-like receptor signaling pathway and stress-activated MAPK pathway ([@B8]; [@B44]). In this regard, the higher expression value of miR-134-3p and miR-15b-5p in AMS− individuals suppresses the expression of genes involved in toll-like receptor signaling pathway and stress-activated MAPK pathway post-transcriptionally, and in turn repress inflammatory response. Thus, the dampened inflammatory response via miRNAs may be a biological factor of AMS− individuals who reveal a higher expression level of miR-134-3p and miR-15b-5p.

The immune system is a highly regulated system to several extrinsic factors including environmental stress ([@B38]). The concept that hypoxia can induce inflammation has also gained credence in some recent studies ([@B11]). Our group has also revealed recently that hypoxia could exacerbate the inflammatory response via stimulating toll-like receptor four signaling pathway in rats ([@B52]). Consistently, several studies in mice have also proposed that hypoxia-induced inflammatory response could result in an enhanced vascular permeability, which is associated with the pathophysiology of AMS development ([@B41]; [@B59]; [@B14]). Interestingly, the present study revealed that the AMS− individuals presented with less severe hypoxemia (higher SpO~2~ and cerebral TOIs) than the AMS+ individuals at high altitude, which was consisted with previous studies ([@B4]; [@B18]; [@B34]; [@B19]; [@B26]). Taken together, hypoxia could be a driver of the inflammatory response, the less severe hypoxemia and the higher expression level of miR-134-3p and miR-15b-5p could alleviate inflammatory response in synergy, thus contributing to AMS prevention.

Limitations {#S4.SS1}
-----------

We demonstrated for the first time, two novel non-invasive salivary miRNAs for identifying AMS− individuals. However, only the young Chinese men were included in this study because they are a part of the population that most frequently travels to high altitudes. Moreover, AMS was diagnosed in the hypobaric chamber, and the rate of ascent was faster than that for a regular travel to high-altitude regions, which may lead to a higher disease incidence. In addition, our participants were all slim, which perhaps could have skewed the results. Therefore, further investigations in high altitude regions, larger sample sizes, different genders, age, race, and BMI, should be studied to affirm the results obtained.

Conclusion {#S5}
==========

In this study, we report for the first time, two non-invasive biomarkers, salivary miR-134-3p and miR-15b-5p, for identifying AMS− individuals pre-exposed to high altitudes. Furthermore, the combination of miR-134-3p and miR-15b-5p may hold a great promise in becoming an important non-invasive tool for AMS prevention in the future.
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